Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
133 results
  • Treatment for hepatitis C virus-associated mixed cryoglobulinaemia. [Review]
    Cochrane Database Syst Rev 2018; 5:CD011403Montero N, Favà A, … Soler MJ
  • CONCLUSIONS: To treat HCV-associated mixed cryoglobulinaemia, it may be beneficial to eliminate HCV infection by using antiviral treatment and to stop the immune response by using rituximab. For skin vasculitis and for some laboratory findings, it may be appropriate to combine antiviral treatment with deletion of B-cell clonal expansions by using of rituximab. The applicability of evidence reviewed here is limited by the absence of any studies with direct-acting antivirals, which are urgently needed to guide therapy.
  • Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. [Journal Article]
    Am J Hematol 2017; 92(7):668-673Sidana S, Rajkumar SV, … Kumar SK
  • We describe a series of 102 patients diagnosed from January 1, 1990 to December 31, 2015 with Type 1 monoclonal cryoglobulinemia (MoC). Symptoms were seen in 89 (87%) patients, including: cutaneous symptoms in 64 (63%) patients, with purpura (n = 43, 42%) and ulcers/gangrene (n = 35, 34%) being most common; neurological findings in 33 (32%) patients, most frequently sensory neuropathy (n = 24, 24…
  • Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia. [Journal Article]
    Am J Gastroenterol 2017; 112(8):1298-1308Emery JS, Kuczynski M, … Feld JJ
  • CONCLUSIONS: DAAs resulted in high rates of SVR in patients with cryoglobulinemia. Safety and tolerability were excellent; however, most patients did not have a complete clinical or immunological response, suggesting a delay to clinical response particularly in those with severe/life-threatening vasculitis. Further follow-up will be required to determine if clinical improvement continues after viral clearance.
New Search Next